Lenalidomide 10 mg Capsule
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Lenalidomide 10 mg Capsule contains lenalidomide, an immunomodulatory medicine. Its labelling describes it for the treatment of multiple myeloma and myelodysplastic syndrome (MDS), a condition in which the bone marrow cannot make enough healthy mature blood cells. It is described as acting on the immune system to slow the growth of abnormal cells and reduce the blood supply to tumours. It is a known teratogen and is subject to a strict pregnancy-prevention programme.
Product Information
The following description reflects information associated with lenalidomide and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the treatment of multiple myeloma
- Described for the treatment of myelodysplastic syndrome (MDS)
- Described as acting on the immune system to slow the growth of abnormal cells and reduce the blood supply to tumours
Described Dosage & Administration
- Swallowed whole at a fixed time each day, before or after a meal, following the doctor’s instructions
- Plenty of water should be taken to stay hydrated
- The dose and duration depend on the condition and may change over time; the course should be completed
Described Side Effects
Commonly described side effects include:
- Headache
- Nausea and diarrhoea
- Rash and itching
- Breathlessness and cough
- Dizziness
- Tiredness (fatigue)
- Decreased white blood cell (neutrophil) count
- Joint pain and back pain
- Decreased appetite
It is also associated with an increased risk of blood clots. Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- It is a known teratogen: it must not be used during pregnancy or breastfeeding, and effective contraception is required for patients of any sex, per the pregnancy-prevention programme
- A medical history should be shared with the healthcare team to avoid an inappropriate medicine combination
- The increased risk of blood clots should be discussed with the doctor
- Any persistent or severe side effect should be reviewed by a clinician
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains lenalidomide and is used to treat multiple myeloma and myelodysplastic syndrome, by acting on the immune system to slow the growth of abnormal cells. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling describes lenalidomide as a known teratogen that must not be used during pregnancy or breastfeeding. Effective contraception is required for patients of any sex under a strict pregnancy-prevention programme; the treating team confirms the specific requirements.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.